

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

APPOINTMENT OF CHIEF OPERATING OFFICER

The board (the “Board”) of directors (the “Directors”) of Yestar Healthcare Holdings Company Limited (the “Company”, which together with its subsidiaries, the “Group”) is pleased to announce that Mr. Chan Chung Man (“Mr. Chan”), an executive Director, has been appointed as the chief operating officer of the Company with effect from 15 March 2018.

Mr. Chan, aged 42, joined the Group in July 2015 as head of medical division of the Group and has been appointed as an executive director of the Company in January 2016. He is also a director of Yestar Biotech (Jiangsu) Company Limited, a wholly-owned subsidiary of the Company. Besides, Mr. Chan is the supervisor for each of Shanghai Emphasis Investment Management Consulting Company Limited, Guangzhou Hongen Medical Diagnostic Technologies Company Limited, Guangzhou Shengshiyuan Trading Company Limited, Shenzhen De Run Li Jia Company Ltd., and Beijing Kaihongda Technology Company Limited, all of which are non-wholly owned subsidiaries of the Company.

Mr. Chan is responsible for the business development, marketing and management of the medical consumable business of the Group. With his extensive experience in merger and acquisitions, Mr. Chan has also assisted the Group to acquire and manage various medical consumable business companies acquired by the Group in the last few years.

Mr. Chan served as a general committee member of the Hong Kong Business Association Vietnam for the period from 2012 to 2013 and from 2014 to 2015. He obtained a Bachelor of Business Administration degree from Lingnan University in 1999 and received a Master of Management degree from Macquarie University in 2003.

Save as disclosed above, Mr. Chan does not hold any other position in the Company or any subsidiaries of the Company nor any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Mr. Chan does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”)) of the Company. Further, Mr. Chan does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) of the Company as at the date of this announcement.

Mr. Chan has been appointed as an executive Director for a term of three years from 29 January 2016, subject to rotation, retirement and re-election by the Shareholders pursuant to the articles of association of the Company. Pursuant to the service agreement dated 29 January 2016 and supplemental agreement entered into between Mr. Chan and the Company, Mr. Chan is entitled to a remuneration of RMB1,856,234 per annum, subject to annual review by the remuneration committee of the Company (the “Remuneration Committee”) and the Board. The remuneration of Mr. Chan has been recommended by the Remuneration Committee based on his qualifications, educational background, work experiences, level of responsibilities to be undertaken and the prevailing market conditions, and approved by the Board.

Save as disclosed above, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, there was no matter relating to the appointment of Mr. Chan as the chief operating officer that needs to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

Hong Kong, 15 March 2018

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Mr. Chan To Keung, Ms. Wang Hong and Mr. Chan Chung Man; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Karsono Tirtamarta (Kwee Yoe Chiang) and Mr. Sutikno Liky.